List of Excipients in Branded Drug TRUSELTIQ

Truseltiq Excipient Strategy and Commercial Opportunities for Infigratinib

Last updated: August 25, 2026

Truseltiq is an oral, immediate-release capsule containing infigratinib phosphate, a selective FGFR2 inhibitor. Its approved commercial formulation uses a conventional lactose-based hard-gelatin capsule with a small excipient set. The strongest excipient opportunities are lifecycle products that preserve exposure while improving swallowing, dietary flexibility, supply resilience, or geographic access. The commercial case is constrained by Truseltiq’s narrow cholangiocarcinoma indication, FGFR2 biomarker requirement, limited patient population, and withdrawal of the U.S. marketing authorization.

What is Truseltiq and which excipients does it contain?

Truseltiq contains infigratinib phosphate and is supplied as 25 mg and 100 mg hard capsules. The FDA-approved regimen is 125 mg once daily for 21 consecutive days followed by seven days off treatment. Patients take the drug on an empty stomach, at least one hour before or two hours after food [1].

The capsule formulation uses common oral solid-dose excipients:

Component	Function in the formulation
Lactose monohydrate	Diluent and bulk-filling agent
Microcrystalline cellulose	Diluent and dry-compression aid
Crospovidone	Superdisintegrant
Colloidal silicon dioxide	Glidant and flow aid
Magnesium stearate	Lubricant
Gelatin capsule shell	Dosage-form enclosure
Titanium dioxide and iron oxide colorants	Capsule identification and strength differentiation

The formulation is operationally simple. It does not rely on a polymeric modified-release system, lipid vehicle, enteric coating, or specialized absorption enhancer. That simplicity reduces manufacturing complexity but leaves several potential lifecycle gaps.

What formulation attributes define the current product?

The principal technical constraint is food administration. Truseltiq labeling requires dosing on an empty stomach because food affects infigratinib exposure [1]. The label also includes clinically important interaction restrictions involving strong or moderate CYP3A inhibitors and inducers, as well as gastric-acid-reducing agents.

The current product therefore has four commercial limitations:

1. It requires scheduled fasting around each dose.
2. It uses lactose, which can restrict use in patients with lactose intolerance or create procurement issues in certain markets.
3. It is available only as a capsule.
4. It requires a 100 mg plus a 25 mg capsule to deliver the recommended 125 mg dose.

These constraints create more practical formulation opportunities than the basic capsule composition itself.

What excipient strategies could improve Truseltiq?

Can a lactose-free capsule create a meaningful opportunity?

A lactose-free version is the clearest low-complexity opportunity. Lactose could be replaced with an alternative diluent system such as mannitol, partially pregelatinized starch, spray-dried mannitol, or additional microcrystalline cellulose.

The commercial value would depend on three factors:

• Whether the replacement changes dissolution or bioavailability.
• Whether the new product can qualify as an equivalent formulation under the applicable regulatory pathway.
• Whether the reformulation can support a differentiated label or only a supply-chain claim.

A lactose-free product would be most useful in markets where excipient declarations influence prescribing, hospital procurement, or patient adherence. It is unlikely to support a large price premium by itself. The stronger business case would combine lactose removal with improved capsule availability, lower manufacturing cost, or a new dosage form.

What excipients could support a smaller or easier-to-swallow capsule?

The 125 mg daily dose is split across two capsule strengths. A higher-load single capsule could reduce pill burden, but achieving that outcome may require:

• Higher drug loading.
• A more efficient granulation process.
• Spray-dried or hot-melt drug-excipient dispersion.
• A smaller capsule shell through improved powder density.
• A new salt, polymorph, or particle-engineering approach.

Infigratinib is a potent small molecule, so a single 125 mg capsule may be technically achievable. The principal development risks are powder flow, content uniformity, dissolution, and stability rather than total drug mass.

A single-capsule product could have greater commercial value than a lactose-free version because it directly reduces daily dosing complexity. It may also lower dispensing errors when patients must cycle treatment.

Is a liquid or sprinkle formulation commercially attractive?

A liquid, powder-for-suspension, or capsule-sprinkle product could address dysphagia, oncology supportive-care needs, and patients unable to swallow hard capsules. The target population would include older adults and patients receiving treatment after biliary or gastrointestinal procedures.

The formulation would require careful control of:

• Drug precipitation and suspension uniformity.
• Taste masking.
• Chemical stability after reconstitution.
• Compatibility with enteral feeding tubes.
• Occupational exposure during preparation.
• Dosing accuracy at 25 mg and 100 mg equivalents.

A liquid product would have a more defensible lifecycle position than an excipient substitution, but its development cost and regulatory burden would be substantially higher. It would be commercially credible only if linked to continued access in a defined market or to a broader infigratinib indication.

What formulation patents could protect a Truseltiq lifecycle product?

New excipient combinations can be protected, but composition-of-matter protection for infigratinib is distinct from formulation protection. A reformulated product may rely on:

• Composition claims covering the drug-excipient ratio.
• Dissolution-profile claims.
• Particle-size or solid-state claims.
• Stabilized formulations.
• Dosage-form claims covering liquids, multiparticulates, or sprinkle capsules.
• Manufacturing-process claims.
• Method-of-use claims tied to improved food administration or reduced variability.

The most defensible formulation patent would normally claim a measurable technical result, such as a defined dissolution profile, improved stability, reduced exposure variability, or equivalent exposure under fed conditions. A patent limited to replacing lactose with another conventional filler would face greater obviousness risk unless the substitution produces an unexpected performance advantage.

A reformulation strategy should be designed around a patentable product profile rather than a simple excipient swap. The formulation work should generate comparative data against the current capsule, including dissolution, fed and fasted pharmacokinetics, stability, moisture sensitivity, and capsule-opening or tube-administration performance.

When does Truseltiq lose exclusivity, and what is the generic entry risk?

Truseltiq is a small-molecule drug, so the principal U.S. competitive pathway is an Abbreviated New Drug Application, not a biosimilar application. Generic applicants may challenge listed patents through Paragraph IV certifications or wait for relevant patent and regulatory exclusivity periods to expire.

The FDA granted accelerated approval in May 2021 for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement [2]. The approval was based on overall response rate and duration of response in the CBGJ398X2204 study.

The U.S. commercial situation has since changed. QED Therapeutics and Helsinn announced the withdrawal of Truseltiq from the U.S. market after the confirmatory development program did not proceed as required for the accelerated approval framework [3]. The withdrawal substantially reduces the near-term value of a U.S.-focused generic or excipient lifecycle program.

Risk area	Assessment
U.S. ANDA competition	Reduced commercial attractiveness after U.S. withdrawal
Paragraph IV litigation	Possible if listed patents remain relevant, but expected value depends on market availability
Biosimilar risk	Not applicable; infigratinib is a small molecule
Ex-U.S. generic risk	Market-specific and dependent on local approvals and patent status
Reformulation risk	Higher regulatory and development risk if the U.S. reference product is unavailable
Patent-based lifecycle value	More relevant in jurisdictions where Truseltiq remains marketed or authorized

The Orange Book should be reviewed for the current patent listing and withdrawal status before relying on any U.S. patent-expiry analysis [4]. Patent protection can remain legally relevant even after commercial withdrawal, but its economic value depends on whether the product can be sold in the jurisdiction.

What is the FDA regulatory status of Truseltiq?

Truseltiq received FDA accelerated approval for a biomarker-selected cholangiocarcinoma population. The indication is restricted to patients with FGFR2 fusions or rearrangements after prior therapy. This narrow label limits the addressable market and places substantial value on diagnostic testing and treatment-line positioning.

The product’s regulatory profile creates three potential formulation pathways:

1. Same drug, improved administration

A lactose-free or higher-load capsule could potentially be developed as a conventional reformulation. The commercial differentiation would be modest unless the product improves dosing convenience or supply reliability.

2. New dosage form

A liquid, sprinkle capsule, or tube-compatible formulation could require a supplemental or new application depending on the jurisdiction and the extent of formulation and labeling changes. The product would need clinical bridging and robust stability data.

3. New indication or broader FGFR use

The highest-value strategy would combine formulation differentiation with a broader clinical program, such as an earlier treatment line or another FGFR2-driven tumor type. That approach would be a drug-development program rather than a conventional excipient lifecycle project.

Which companies are positioned to challenge or license Truseltiq?

The original commercial rights were associated with QED Therapeutics and Helsinn. Helsinn entered into a collaboration with QED to commercialize infigratinib in the United States and Europe [5]. BridgeBio Pharma identified QED as the operating company responsible for infigratinib development.

Potential counterparties for an excipient-led lifecycle program would include:

• Specialty oncology companies with FGFR or precision-medicine portfolios.
• Generic manufacturers with oncology capsule capacity.
• CDMOs able to produce high-content oral solid doses.
• Regional licensees in markets where FGFR2 testing and cholangiocarcinoma treatment are established.
• Diagnostic companies supporting FGFR2 fusion and rearrangement testing.

The most practical transaction would be a regional license or supply agreement tied to an improved capsule or oral liquid. A global acquisition based solely on a lactose-free formulation would have limited strategic justification.

How strong is the commercial opportunity for an improved Truseltiq formulation?

The opportunity is selective rather than broad. Cholangiocarcinoma is a rare cancer, and only a biomarker-defined subset is eligible for infigratinib. Treatment requires molecular testing, and the label is directed to previously treated disease.

High-value opportunities

• A single 125 mg capsule that reduces pill burden.
• A formulation that removes the need for fasting administration, if clinically demonstrated.
• A liquid or sprinkle product for patients with swallowing or administration barriers.
• Regional products for markets with continuing access to infigratinib.
• A stable, low-cost formulation that improves supply reliability.

Lower-value opportunities

• A simple colorant change.
• A conventional lactose-to-mannitol substitution without clinical benefit.
• A new capsule shell without improved administration.
• A reformulation designed solely for the U.S. market after commercial withdrawal.
• A product that does not address food restrictions, dosing burden, or patient access.

Public sources do not establish a current, standalone Truseltiq revenue base that would support a large U.S. excipient investment. The investment case should therefore be based on regional market access, licensing rights, development cost, and the ability to secure formulation or process patents.

What generic launch scenarios exist for Truseltiq?

Scenario 1: Conventional capsule generic

A generic manufacturer would reproduce the immediate-release capsule and pursue local generic approval. This is the lowest-cost pathway but offers limited differentiation and depends on an active commercial reference product.

Scenario 2: Lactose-free or high-load capsule

This approach could create a differentiated product while preserving oral solid-dose manufacturing. It would require comparative dissolution and pharmacokinetic work. The product could compete in markets where the innovator remains commercially available.

Scenario 3: Patient-centric dosage form

A liquid, sprinkle, or tube-compatible product could capture a narrower but more defensible segment. It would require stronger clinical and handling data but could support licensing to specialty oncology distributors.

Scenario 4: Regional infigratinib platform

A company could combine manufacturing rights, local regulatory approval, FGFR2 diagnostic access, and a reformulated product. This is the most commercially coherent strategy where U.S. market withdrawal has reduced direct reference-product competition.

What manufacturing and IP barriers affect the opportunity?

The active pharmaceutical ingredient and analytical standards remain critical barriers. A prospective entrant must establish control over:

• Infigratinib phosphate supply.
• Polymorphic and particle-size characteristics.
• Impurity limits and degradation pathways.
• Content uniformity at the 25 mg strength.
• Capsule color and identification controls.
• Photostability and moisture stability.
• Bioequivalence under the labeled fasting condition.
• Compatibility with alternative excipients.

The strongest IP position would combine formulation claims with process claims and, where supportable, claims covering a defined solid form or particle-engineered material. Manufacturing know-how can provide practical protection even where formulation patent scope is narrow.

Key Takeaways

• Truseltiq is an immediate-release infigratinib capsule supplied in 25 mg and 100 mg strengths.
• The formulation uses lactose monohydrate, microcrystalline cellulose, crospovidone, colloidal silicon dioxide, magnesium stearate, and a hard-gelatin shell.
• A lactose-free capsule is technically straightforward but has limited standalone commercial value.
• A single 125 mg capsule, fed-condition formulation, liquid, sprinkle product, or enteral-tube formulation has greater differentiation potential.
• Truseltiq’s U.S. withdrawal reduces the value of a U.S.-focused generic or excipient strategy.
• The strongest opportunity is regional licensing tied to an improved dosage form, active market access, and FGFR2 diagnostic infrastructure.
• Infigratinib is a small molecule, so ANDA and Paragraph IV pathways are relevant; biosimilar competition is not.
• Formulation patents should be built around measurable performance advantages, not routine excipient substitution.

FAQs

Can Truseltiq be reformulated without lactose?

Yes. Lactose can potentially be replaced with mannitol, starch-based diluents, or additional microcrystalline cellulose, subject to dissolution, stability, and bioequivalence requirements.

Would a liquid infigratinib formulation qualify for pediatric use?

Not automatically. A liquid dosage form could improve administration, but pediatric use would require an appropriate clinical and regulatory development program.

Can a generic manufacturer sell infigratinib after U.S. Truseltiq withdrawal?

U.S. approval would depend on the FDA’s reference-product, withdrawal, patent, exclusivity, and application requirements. Commercial feasibility would also depend on whether an active U.S. market exists.

What is the most valuable excipient improvement for infigratinib?

A formulation that permits dosing without fasting would have the greatest potential clinical value, but it would require pharmacokinetic evidence and likely a more extensive regulatory package than a lactose-free capsule.

Is infigratinib vulnerable to biosimilars?

No. Infigratinib is a chemically synthesized small molecule. Competition would arise through generic-drug pathways rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2024). Truseltiq (infigratinib) prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/214622s004lbl.pdf
2. U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to infigratinib for metastatic cholangiocarcinoma. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-infigratinib-metastatic-cholangiocarcinoma
3. U.S. Food and Drug Administration. (2024). Withdrawal of approval of the new drug application for Truseltiq. Federal Register. https://www.federalregister.gov/
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
5. Helsinn Healthcare SA. (2021). Helsinn and QED Therapeutics announce U.S. commercial availability of Truseltiq. https://www.helsinn.com/news/